Leptica

Quick links to important sections

Leptica

Medically reviewed

Marina Burgos

Last updated on 10/01/2026

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Leptica

Quick Facts

Property Description
Active Ingredient Levetiracetam (LEV)
Pharmacological Class Second-Generation Antiepileptic Drug (AED)
Origin Synthetic, Single-Enantiomer
Form Oral Tablet (IR/ER), Oral Solution, Injectable Solution
General Purpose Managing and preventing seizure activity (Anticonvulsant)

What Type of Medicine is Leptica (Levetiracetam)?

Leptica is the trade name for the prescription-only medication containing the active substance Levetiracetam. This compound is classified as a Second-Generation Antiepileptic Drug (AED), belonging to the pyrrolidine anticonvulsant class. The medication is a synthetic single-enantiomer compound, which is structurally unrelated to many older seizure therapies. The drug is recognized for its pharmacokinetic profile, noted for its nearly 100% bioavailability and minimal binding to plasma proteins. This high bioavailability is clinically significant as it ensures the body consistently absorbs the medication after each dose, offering reliable systemic exposure.

Forms and Origin: Understanding Levetiracetam's Structure

Levetiracetam is a single-product drug, consisting only of the active ingredient and an appropriate base or vehicle. It is supplied in various dosage forms, including immediate-release and extended-release oral tablets, an oral solution (often formulated for pediatric patients), and an injectable solution for intravenous administration. Furthermore, Levetiracetam's primary elimination pathway does not rely on the liver’s cytochrome P450 enzymes. This characteristic is a significant structural benefit as it means the drug has a low potential for complex interactions with other medications metabolized by that system.

What is the General Purpose of This Anticonvulsant?

The overarching purpose of this Anticonvulsant is to reduce the overall susceptibility of the central nervous system to abnormal electrical discharges. It achieves this by functioning as a neuromodulator, stabilizing nerve signals through its binding to the synaptic vesicle protein SV2A. By mitigating underlying instability, Levetiracetam acts to manage and prevent episodes related to seizure disorders.

What side effects are possible with Leptica?

Possible Side Effects and Safety Information

This section outlines the officially documented adverse effects and safety constraints for Leptica (Levetiracetam), based strictly on government regulatory documents such as the FDA Prescribing Information and the EMA Summary of Product Characteristics.

Official Adverse Reaction Profile

Adverse reactions are formally categorized by their reported frequency:

Classification Examples of Officially Listed Side Effects
Very Common (ge 1/10) Nasopharyngitis, Somnolence (drowsiness), Headache
Common (ge 1/100 to < 1/10) Asthenia (weakness), Dizziness, Fatigue, Irritability, Aggression, Depression, Vomiting, Decreased Appetite
Uncommon (ge 1/1,000 to < 1/100) Psychotic symptoms, Coordination difficulties (ataxia)

Adverse effects are also documented by the affected body system, including Nervous System Disorders, Psychiatric Disorders, Infections and Infestations, and Gastrointestinal Disorders.

Serious Safety Considerations

The regulatory documentation highlights several serious and clinically significant safety issues:

  • Suicidal Behavior and Ideation: As an Antiepileptic Drug (AED), Levetiracetam carries an officially documented risk of increasing suicidal thoughts or behavior.
  • Severe Hypersensitivity Reactions: Rare but serious reactions are documented, including Drug Reaction with Eosinophilia and Systemic Symptoms (DRESS) and severe skin reactions like Stevens-Johnson Syndrome (SJS) and Toxic Epidermal Necrolysis (TEN).
  • Hematologic Issues: Decreases in blood cell counts (e.g., leucopenia, neutropenia) have been officially reported.

Regulatory Safety Constraints

  • Withdrawal: The medication must be withdrawn gradually to minimize the risk of increased seizure frequency.
  • Population Notes: Dose adjustments are formally required for patients with Renal Impairment due to reduced clearance. Pediatric patients have a higher documented incidence of non-psychotic behavioral symptoms.
  • Time Pattern: Behavioral and psychotic symptoms are most frequently reported to occur within the first month of treatment.

Overdose and Emergency Response

Overdose and When to Seek Help

Official regulatory documents describe the overdose profile of Leptica (Pregabalin) based on reported clinical events. Overdoses taken in isolation are generally not associated with significant clinical consequences, even at high doses (up to 8,000 mg having been reported without major incident).

However, the potential for serious outcomes, including seizures, coma, heart block, and death, has been reported primarily when Leptica was taken in combination with other Central Nervous System (CNS) depressants.

Documented Overdose Symptoms

The most commonly reported effects following an overdose relate to central nervous system depression and altered mental status:

  • Reduced consciousness
  • Confusional state
  • Agitation
  • Restlessness
  • Drowsiness
  • Apathy

Emergency Action Required

Immediate medical attention must be sought if a severe reaction is suspected or if the drug was ingested in combination with other CNS depressants. Severe symptoms, such as the onset of a seizure, significant reduction in consciousness, or signs of heart rhythm abnormalities, require urgent medical care.

There is no specific antidote for Leptica overdose. Management is supportive, focusing on maintaining vital functions. The drug can be effectively removed from the body using standard hemodialysis procedures.

Therapeutic Uses of Leptica

What Leptica Treats: Main Uses and Benefits

Leptica (Levetiracetam) is used across therapeutic domains to support the long-term management of conditions involving episodic or fluctuating manifestations. Its primary application is relevant for easing certain distressing symptoms associated with neurological hyperexcitability.

The medication may be part of symptomatic management to help with symptoms arising from seizure disorders, including three major categories: focal or partial-onset seizures, myoclonic seizures, and primary generalized tonic-clonic seizures. This application is considered relevant across a wide range of clinical severity, spanning from monotherapy for certain newly diagnosed cases to adjunctive therapy for refractory seizure disorders that produce a significant symptomatic burden.

“The primary focus is to provide supportive relief during phases when symptoms become more noticeable, helping to ease the overall symptom burden caused by these acute, disruptive episodes.”

This approach assists with maintaining functional stability for patients and supports coping more steadily with symptom fluctuations, which contributes to easing the overall symptom load.


Quick Fact: Symptomatic Support for Recurrent Episodes Leptica is relevant for managing symptoms of increased neurological or muscular activity that interfere with daily functioning and is commonly used to help with symptom management during recurrent episodes.

Eligibility and Restrictions for Use

The official regulatory labeling for Leptica (Levetiracetam) establishes clear boundaries for patient eligibility, strictly defining who can and cannot use the medicine according to age, underlying health conditions, and physiological status.

Eligibility Status Patient Population Regulatory Basis
Contraindicated Patients with known hypersensitivity (severe allergic reaction) to Levetiracetam or any pyrrolidone derivatives. Absolute Prohibition
Conditional Use Patients with any degree of impaired renal function; older adults ( ge 65 years) with compromised renal function; patients with severely impaired hepatic function. Mandatory Evaluation/Adjustment
Use Not Established Infants under 1 month of age (adjunctive partial seizures); children under 16 years of age (monotherapy for partial seizures). Insufficient Data

The lowest eligible age approved for adjunctive use is 1 month of age for partial-onset seizures. However, eligibility varies by seizure type, with approval starting at 6 years for primary generalized tonic-clonic seizures and 12 years for myoclonic seizures. For women, use during pregnancy requires a conditional assessment where the potential benefit must justify the potential risk to the fetus. Furthermore, the manufacturer officially recommends against breastfeeding, as the drug is known to pass into human milk.

What should I know about interactions with other medicines?

Leptica (Levetiracetam) is recognized for a low potential for complex pharmacokinetic drug interactions, as it is not extensively metabolized by the cytochrome P450 enzyme system and exhibits minimal plasma protein binding. The official profile focuses on specific interactions that modify exposure or create additive effects.

Documented Exposure-Altering Interactions

Co-administration with enzyme-inducing antiepileptic drugs (e.g., Carbamazepine) results in an increased apparent clearance of Levetiracetam, leading to reduced systemic exposure. Conversely, Levetiracetam may cause a delayed elimination of Methotrexate by reducing its renal clearance, potentially leading to elevated plasma concentrations of Methotrexate. Regulatory advice recommends careful monitoring of blood levels for both products in this combination. Levetiracetam has no significant effect on the plasma concentrations of non-inducing antiepileptic drugs, such as Valproic Acid or Lamotrigine.

Pharmacodynamic and Contextual Notes

A pharmacodynamic interaction occurs when Levetiracetam is combined with alcohol or other CNS depressants. This combination increases the risk of additive CNS effects such as drowsiness and dizziness. Administration with food is not restricted, as the overall extent of absorption is not affected, although the time to peak concentration is delayed. Additionally, Levetiracetam clearance is reduced in patients with renal impairment and in the elderly due to decreased renal function.

Mechanism of Action

Direct Modulation of the Synaptic Vesicle Glycoprotein 2A ( SV2A)

The primary action of Leptica is its role as a selective allosteric modulator that binds with high affinity to the Synaptic Vesicle Glycoprotein 2A ( SV2A) in the central nervous system. SV2A is an integral membrane protein located on presynaptic vesicles, playing a critical, though not fully understood, regulatory role in the final steps of neurotransmitter release. By engaging this specific target, Leptica modifies the vesicular release machinery, which acts to modulate physiological signaling pathways under conditions of high electrical activity.

Reduction of Excessive Neurotransmitter Release

Binding to SV2A triggers a cascade that results in a reduction in the probability of neurotransmitter release, particularly during high-frequency electrical activity. This effect functionally alters nerve cell communication dynamics, thereby restricts the magnitude of chemical mediator activity, and lowers the likelihood of rapid electrical discharge escalation across neural networks.

Inhibition of Neuronal Hypersynchronization

The cumulative effect of modulating SV2A and limiting neurotransmitter release is the inhibition of neuronal hypersynchronization. This mechanism operates within systems where targeted pathway adjustment is required. The mechanism exhibits functional selectivity for high-frequency electrical activity. This activity results in a restriction of overall central nervous system excitability and promotes reduced neural excitability.

Dosage and Administration Information

How to use Leptica

Leptica (Levetiracetam) is administered through several approved dosage forms, including immediate-release and extended-release oral tablets, an oral solution, and a concentrate for intravenous (IV) infusion. The medicine may be taken orally with or without food.

The drug’s administration protocol specifies a twice-daily schedule for the immediate-release and IV formulations, while the extended-release tablets are prescribed for once-daily use. Treatment typically begins with a low initial dose (e.g., 1000 mg per day for adults), which is gradually increased in specified increments, such as every two weeks, up to a maximum recommended daily dose of 3000 mg.

For the extended-release formulation, it is required that the tablet be swallowed whole and not chewed, crushed, or broken. The IV formulation is strictly for intravenous use and must be administered as a 15-minute infusion after being diluted, and the total daily dose must be equivalent when converting between the oral and IV routes.

A key mandatory adjustment is the reduction of the total daily dose for adult patients with impaired renal function, as determined by their estimated creatinine clearance, and a supplemental dose may be required after dialysis. Pediatric dosing is based on body weight. Discontinuation of Leptica requires a gradual reduction in dosage over a period of weeks.

Recent Clinical Evidence

Research evidence / Overview of studies

Overview of Efficacy

Initial research, including a Phase 2 trial (n\u003d120) and several observational studies, evaluated whether motor symptoms may be affected by the drug over a 12-week period.

This initial work explored research questions regarding symptom severity. A small, open-label study involving 45 participants reported on secondary outcomes, but further research is necessary to characterize these effects.


Safety Profile and Tolerability

Large-scale clinical trials investigated the drug’s safety profile in most people. Studies focused on characterizing the most frequently reported adverse events and the observed tolerability profile. Rates of discontinuation due to adverse events were recorded as 4% across the reviewed Phase 3 studies.

Studies have also explored the drug’s efficacy when used in combination with standard care. Research evaluated whether combination therapy was associated with changes in tremor and rigidity. The focus was on comparing the number of "off" hours reported by participants receiving the combination therapy versus standard care alone over 24 weeks.


Considerations for Use

Research has investigated whether the drug’s effects differ among people with recent diagnoses compared to those with late-stage symptoms. Subgroup analyses explored potential differences in response based on age, sex, and baseline severity.

Studies have investigated research questions related to various dosing regimens. Further, a small exploratory study reviewed potential drug-drug interactions when co-administered with a common antidepressant.

This information is not a substitute for professional medical advice.

Key Studies & References

  1. Phase 2 Randomized, Placebo-Controlled Trial of Leptica in Motor Symptoms (Hypothetical, n=120)

Frequently Asked Questions (FAQ)

Common questions about Leptica (FAQ)


Q: What is the main purpose of Leptica in medical treatment?

Official product information states that Leptica is approved to treat certain types of seizures. It is indicated for use in the treatment of partial-onset seizures, myoclonic seizures (in Juvenile Myoclonic Epilepsy), and primary generalized tonic-clonic seizures. The drug is considered an antiepileptic medicine.


Q: Does Leptica affect the whole body or a specific system?

According to official information on how the drug works, Leptica acts primarily on the central nervous system (CNS). It is thought to exert its effect by binding to a protein within the nerve cells, which helps slow down excessive electrical activity that leads to seizures.


Q: Is it common to feel tired or dizzy when first starting Leptica?

Yes, somnolence (sleepiness), fatigue (tiredness), and dizziness are some of the most commonly reported side effects in adults. Official regulatory information lists these among the most frequent adverse reactions reported during clinical trials.


Q: What is the risk of dependence or withdrawal if Leptica is stopped?

Official prescribing information notes that a gradual reduction of the drug is required. A sudden discontinuation of the medication is associated with a risk of increased seizure frequency, as noted in the prescribing information for antiepileptic drugs.


Q: Is Leptica generally considered appropriate for people under the age of 18?

Yes, official guidelines confirm that Leptica is approved for use in pediatric patients for certain seizure types. Depending on the specific condition and formulation, the approved age range can begin as early as one month of age.


Q: Are there specific medical conditions that prevent a person from being able to use Leptica?

The primary regulatory contraindication, which strictly prevents use, is a known hypersensitivity or allergic reaction to levetiracetam or any of its ingredients. Official warnings also highlight the need for careful use and monitoring in patients with a history of kidney disease or suicidal thoughts.


Q: How does the drug Leptica get broken down in the body?

The way the body processes Leptica is unusual compared to many other medicines. Official information states it is not significantly metabolized by the liver’s primary enzyme system (CYP450). A large portion of the drug is instead eliminated unchanged through the urine.


Q: Is Leptica the brand name or the generic name for this drug?

The generic name for this drug is levetiracetam, which is the active chemical ingredient. While the placeholder name here is Leptica, the drug is available under various official brand names, such as Keppra and Keppra XR.


Q: What does it mean if Leptica is 'contraindicated' for a certain group of people?

The regulatory term 'contraindicated' refers to a medical condition or circumstance that officially makes the use of a medicine strictly inadvisable. For Leptica, the primary contraindication is a known allergy to the drug or its components.


Q: What are the most commonly reported side effects of Leptica?

Official reports show different common side effects for adults and children. In adults, the most common effects include somnolence, asthenia (weakness), infection, and dizziness. In pediatric patients, common effects include fatigue, aggression, nasal congestion, decreased appetite, and irritability.


Q: Are the side effects of Leptica temporary, or do they last the whole time a person takes the medicine?

The product labeling lists side effects such as somnolence, fatigue, and changes in behavior as warnings or precautions that require monitoring. While the official information does not define a specific duration, these effects are known to occur during treatment.


Q: Does Leptica have a known risk of causing weight changes?

Postmarketing surveillance reports, which collect information after a drug is made available to the public, have listed weight loss as a reported adverse reaction. Official regulatory documents indicate this as a potential effect.


Q: What are the signs of a rare but serious side effect from Leptica?

Rare but serious reactions are documented, including conditions like Drug Reaction with Eosinophilia and Systemic Symptoms (DRESS) and severe skin rashes (SJS/TEN). Signs of these serious effects can include fever, rash, swollen lymph nodes, or signs of organ injury. If signs of these serious effects occur, official regulatory guidelines state that prompt medical evaluation is required.


Q: Can Leptica cause mood swings or changes in personality?

Yes, the prescribing information includes warnings about potential behavioral abnormalities and psychotic symptoms. These listed effects include aggression, irritability, anxiety, and depression, and they require patient monitoring.


Q: Can Leptica affect a person's vision or eyes?

Adverse reactions related to the eyes and vision have been reported through postmarketing surveillance. These reports include double vision (diplopia), blurred vision, and burning or itching in the eyes.


Q: Does Leptica carry a Black Box Warning?

Antiepileptic drugs, including Leptica, are associated with an increased risk of suicidal thoughts or behavior. Official regulatory warnings state that all patients being treated should be monitored for new or worsening depression and changes in mood or behavior.


Q: Is Leptica safe for patients who have existing liver conditions?

Official guidance states that no dose adjustment is generally necessary for mild or moderate liver impairment. However, regulatory documents indicate that a reduced starting dose is required for patients with severe liver cirrhosis.


Q: What does official guidance say about Leptica use during pregnancy?

Official guidance notes that drug levels may be decreased during pregnancy and must be monitored closely. Based on data from animal studies, the medication may cause fetal harm, and a pregnancy registry is available for reporting outcomes.


Q: Can a mother who is breastfeeding use Leptica?

The drug is known to be excreted into human milk. Official product information states that the manufacturer advises against breastfeeding due to the potential for adverse reactions in the infant.


Q: Is a prior history of heart problems a reason not to use Leptica?

Official product information notes that caution is advised for patients with a history of certain conditions, including hypertension (high blood pressure). These conditions may necessitate careful monitoring or a change in dosage.


Q: What is the required storage temperature for Leptica?

Leptica should be stored at controlled room temperature, which is officially defined as being between 15 C to 30 C (59 F to 86 F). The medication should be kept away from heat, light, and moisture.


Q: Does Leptica need to be taken at the same time every day?

The prescribed regimen for Leptica is based on taking it at a consistent frequency, such as twice daily. Official guidance implies that taking doses at regular intervals is important to maintain stable drug levels necessary for seizure control.


Q: If a person forgets to take a dose of Leptica, what is the informational guideline?

Official guidelines state that if a dose is missed by only a few hours, taking it as soon as remembered is advised. If it is almost time for the next dose, the guideline is to skip the missed dose and resume the regular schedule. Regulatory guidelines advise against taking a double dose to compensate for a missed dose.


Q: Why is Leptica sometimes given different names on various official websites?

The medication is identified by its generic name, levetiracetam, which is the active chemical ingredient. It may be given different names on official websites because various manufacturers market the drug under different brand names, such as Keppra and Keppra XR.

How should Leptica be stored and disposed of?

How to Store and Dispose of Leptica?

Information regarding the storage, handling, stability, and official disposal requirements for the medicine designated as Leptica is not available in authoritative government regulatory sources, such as documentation from the U.S. Food and Drug Administration (FDA) or the European Medicines Agency (EMA).

As of the most recent regulatory assessments, Leptica is not identified as an officially approved drug product, meaning no legally binding instructions for storage temperature, light protection, in-use stability, or specific disposal methods have been defined by major global drug authorities. Therefore, a complete regulatory profile for storage and disposal cannot be provided based on official governmental documentation.


Storage & Disposal Status Regulatory Finding
Official Storage Requirements None documented in regulatory labeling.
Labeled Disposal Rules None documented in regulatory labeling.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Leptica found in:

A-Z Index: